Note 14. Notes Payable

 

Notes payable consisted of the following (in thousands):

 

  

December 31, 2025

  

December 31, 2024

 

A. Mortgage note payable - commercial bank - collateralized

 $956  $1,050 

B. Note payable - uncollateralized

  25   25 

C. Notes payable - collateralized

  78   234 

Insurance premiums financing

  233   103 

Subtotal

  1,292   1,412 

Less: current portion of notes payable

  (416)  (380)

Long-term portion of notes payable

 $876  $1,032 

 

(A) Mortgage Note Payable – collateralized

 

In 2018, Pharmco closed on the purchase of land and building located at 400 Ansin Boulevard, Hallandale Beach, Florida. The purchase price was financed in part through a mortgage note and security agreement entered into with a commercial lender in the amount of $1,530,000. The promissory note is collateralized by the land and building, bears interest at a fixed rate of 4.75% per annum, matures on December 14, 2028 and is subject to a prepayment penalty. Principal and interest are repaid through 119 regular payments of $11,901 that began in January 2019, with the final payment of all principal and accrued interest not yet paid on December 14, 2028. Note repayment is guaranteed by Progressive Care. The carrying value of the land and building was approximately $2.2 million as of December 31, 2025.

 

(B) Note Payable – Uncollateralized

 

As of  December 31, 2025, the uncollateralized note payable represents a non-interest-bearing loan that is due on demand from an investor.

 

(C) Notes Payable – Collateralized

 

On July 16, 2020 (the “Issue Date”), GTC, entered into a Coronavirus Interruption Loan Agreement (“Debenture”) by and among the Company and HSBC UK Bank PLC (the “Lender”) for an amount of £250,000, or USD $338,343 at an exchange rate of GBP: USD of 1.3533720. The Debenture bears interest beginning July 16, 2021, at a rate of 4.0% per annum over the Bank of England Base Rate (0.1% as of July 16, 2020), payable monthly on the outstanding principal amount of the Debenture. The Debenture has a term of six years from the drawdown date and is scheduled to mature on July 15, 2026 (the “Maturity Date”). Voluntary prepayments are allowed with five business days’ written notice and the amount of the prepayment is equal to 10% or more of the limit or, if less, the balance of the debenture. The Debenture is secured by all GTC’s assets as well as a guarantee by the UK government. The Debenture includes customary events of default, including, among others: (i) non-payment of amounts due thereunder, (ii) non-compliance with covenants thereunder, (iii) bankruptcy or insolvency (each, an “Event of Default”). Upon the occurrence of an Event of Default, the Debenture becomes payable upon demand. The balance outstanding on the note payable was approximately $39,000 and $132,000 as of  December 31, 2025 and 2024, respectively.

 

In July 2022, Progressive Care entered into a note obligation with a commercial lender, the proceeds from which were used to purchase pharmacy equipment in the amount of approximately $90,000. The terms of the promissory note payable require 60 monthly payments of $1,859, including interest at 8.78% starting January 2023. The balance outstanding on the note payable was approximately $39,000 and $58,000 as of  December 31, 2025 and 2024, respectively.

 

Principal outstanding as of  December 31, 2025, is expected to be repayable as follows (in thousands):

 

Year

 

Amount

 

2026

 $416 

2027

  123 

2028

  753 

Thereafter

   

Total

 $1,292 

   

Historical Timeline

Fiscal YearFiled
2025Mar 31, 2026Showing above
2024Mar 24, 2025

About Debt Disclosures

Debt disclosures detail a company's borrowing structure — the types of instruments, interest rates, maturity schedule, and covenant restrictions that define its financial obligations and flexibility. This section is essential for assessing refinancing risk, interest rate exposure, and the margin of safety against financial distress.

Key signals: the maturity schedule reveals concentration risk — large maturities within 1-2 years during tight credit markets can force dilutive refinancing or asset sales. Compare the fair value of debt against carrying amount to gauge whether the market views the company's credit risk differently than the balance sheet suggests. Watch covenant compliance disclosures for tightening cushions, especially leverage and interest coverage ratios. Variable-rate debt exposure quantifies sensitivity to interest rate changes. Secured versus unsecured mix affects recovery rates and future borrowing capacity. Compare net debt-to-EBITDA against industry peers and covenant limits to assess financial health.